Gary L. Lensmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gary L. Lensmeyer has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Donald A Wiebe
Clinical Toxicology Laboratory, University of Wisconsin Hospital and Clinics
1 shared publicationDonald A. Wiebe
Clinical Laboratories and Departments of Pathology and Laboratory Medicine, University of Wisconsin Hospital , 600 Highland Avenue, Madison, Wisconsin 53792
1 shared publicationIan H. Carlson
Clinical Laboratories and Departments of Pathology and Laboratory Medicine, University of Wisconsin Hospital , 600 Highland Avenue, Madison, Wisconsin 53792
1 shared publicationMarc K. Drezner
Department of Medicine Osteoporosis Clinical Center and Research Program, University of Wisconsin-Madison, and Geriatric Research, Education and Clinical Center, William S. Middleton Veterans Affairs Medical Center, Madison, WI
1 shared publicationNeil Binkley
Department of Medicine Osteoporosis Clinical Center and Research Program, University of Wisconsin-Madison, and Geriatric Research, Education and Clinical Center, William S. Middleton Veterans Affairs Medical Center, Madison, WI
1 shared publicationRamiah Subramanian
Clinical Laboratories and Departments of Pathology and Laboratory Medicine, University of Wisconsin Hospital , 600 Highland Avenue, Madison, Wisconsin 53792
1 shared publication
Latest Publications
- 1 June 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (6) , 1120-1126
HPLC Method for 25-Hydroxyvitamin D Measurement: Comparison with Contemporary Assays
Background: The concentration of 25-hydroxyvitamin D [25(OH)D] in serum has been designated the functional indicator of vitamin D (VitD) nutritional status. Unfortunately, variability among 25(OH)D assays limits clinician ability to monitor VitD status, supplementation, and toxicity. Methods: We developed an HPLC method that selectively measures 25-hydroxyvitamin D2 [25(OH)D2] and D3 [25(OH)D3] and compared this assay with a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method, a competitive protein-binding assay (CPBA) on the Nichols Advantage™ platform, and an RIA from Diasorin. Results: For the new HPLC assay, between-run CVs were 2.6%–4.9% for 25(OH)D3 and 3.2%–13% for 25(OH)D2; recoveries were 95%–102%; and the assay was linear from 5 μg/L to at least 200 μg/L. Comparison data were as follows: for HPLC vs LC-MS/MS, y = 1.01x − 4.82 μg/L (Sy|x = 4.93 μg/L; r = 0.996) for 25(OH)D3, and y = 0.902x − 0.566 μg/L (Sy|x = 2.56 μg/L; r = 0.9965 for 25(OH)D2; for HPLC vs Diasorin RIA, y = 0.709x − 5.86 μg/L (Sy|x = 7.35 μg/L; r = 0.7509); and for HPLC vs Nichols Advantage CPBA, y = 1.00x − 3.60 μg/L (Sy|x = 32.7 μg/L; r = 0.6823). Conclusions: The new HPLC method is reliable, robust, and has advantages compared with the Nichols Advantage CPBA and the Diasorin RIA. The Nichols Advantage CPBA overestimated or underestimated 25(OH)D concentrations predicated on the prevailing metabolite present in patients’ sera.
- 1 June 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (6) , 1120-1126
HPLC Method for 25-Hydroxyvitamin D Measurement: Comparison with Contemporary Assays
Background: The concentration of 25-hydroxyvitamin D [25(OH)D] in serum has been designated the functional indicator of vitamin D (VitD) nutritional status. Unfortunately, variability among 25(OH)D assays limits clinician ability to monitor VitD status, supplementation, and toxicity. Methods: We developed an HPLC method that selectively measures 25-hydroxyvitamin D2 [25(OH)D2] and D3 [25(OH)D3] and compared this assay with a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method, a competitive protein-binding assay (CPBA) on the Nichols Advantage™ platform, and an RIA from Diasorin. Results: For the new HPLC assay, between-run CVs were 2.6%–4.9% for 25(OH)D3 and 3.2%–13% for 25(OH)D2; recoveries were 95%–102%; and the assay was linear from 5 μg/L to at least 200 μg/L. Comparison data were as follows: for HPLC vs LC-MS/MS, y = 1.01x − 4.82 μg/L (Sy|x = 4.93 μg/L; r = 0.996) for 25(OH)D3, and y = 0.902x − 0.566 μg/L (Sy|x = 2.56 μg/L; r = 0.9965 for 25(OH)D2; for HPLC vs Diasorin RIA, y = 0.709x − 5.86 μg/L (Sy|x = 7.35 μg/L; r = 0.7509); and for HPLC vs Nichols Advantage CPBA, y = 1.00x − 3.60 μg/L (Sy|x = 32.7 μg/L; r = 0.6823). Conclusions: The new HPLC method is reliable, robust, and has advantages compared with the Nichols Advantage CPBA and the Diasorin RIA. The Nichols Advantage CPBA overestimated or underestimated 25(OH)D concentrations predicated on the prevailing metabolite present in patients’ sera.
- 1 May 1991
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 15 (3) , 110-115
Concentrations of Cyclosporin A and Its Metabolites in Human Tissues Postmortem
We report concentrations and distribution of cyclosporine A (CsA) and individual metabolites associated with various organ tissues and whole-blood specimens collected at autopsy from seven transplant patients who received CsA therapy. Solid-phase extraction (SPE) and specific high-performance liquid chromatographic (HPLC) procedures were used to separate and quantitate the cyclosporines. Patterns of deposition were unique for the various tissue types. Metabolites M17, M1, M18, and M8 (in addition to CsA) were the principal compounds detected in significant quantities. On a per weight basis, the sum concentration of CsA and metabolites in organ tissues was up to 53 times greater than in companion whole-blood specimens. Metabolite M17 prevailed in most tissues, except in fat and pancreas, where CsA was predominant. Overall, pancreas specimens contained a greater concentration of cyclosporines (per kilogram of tissue), followed consecutively by spleen, liver, fat, kidney, lung, bone marrow, heart, and whole blood. No CsA-related compounds were detected in brain or spinal cord tissue.
- 1 May 1991
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 15 (3) , 110-115
Concentrations of Cyclosporin A and Its Metabolites in Human Tissues Postmortem
We report concentrations and distribution of cyclosporine A (CsA) and individual metabolites associated with various organ tissues and whole-blood specimens collected at autopsy from seven transplant patients who received CsA therapy. Solid-phase extraction (SPE) and specific high-performance liquid chromatographic (HPLC) procedures were used to separate and quantitate the cyclosporines. Patterns of deposition were unique for the various tissue types. Metabolites M17, M1, M18, and M8 (in addition to CsA) were the principal compounds detected in significant quantities. On a per weight basis, the sum concentration of CsA and metabolites in organ tissues was up to 53 times greater than in companion whole-blood specimens. Metabolite M17 prevailed in most tissues, except in fat and pancreas, where CsA was predominant. Overall, pancreas specimens contained a greater concentration of cyclosporines (per kilogram of tissue), followed consecutively by spleen, liver, fat, kidney, lung, bone marrow, heart, and whole blood. No CsA-related compounds were detected in brain or spinal cord tissue.